 |
|
Annual prostate cancer screening test appears to save lives
October 20, 2005Men who have a yearly blood test to examine their prostate specific antigen levels are nearly three times less likely to die from prostate cancer than those who don't have annual screenings, according to a study presented October 19, 2005, at the American Society for Therapeutic Radiology and Oncology's 47th Annual Meeting in Denver.
The study shows that over an estimated 10-year period, men who have an annual prostate specific antigen (PSA) test will have a 3.6 percent chance of dying from the disease, compared to 11.3 percent in the general population. Patients who have the test are more likely to be diagnosed with prostate cancer that is curable in the vast majority of cases, as opposed to aggressive cancers that are less likely to be curable.
"The PSA blood test is the best simple screening test available for prostate cancer that picks up prostate cancer earlier, while it's still curable," said Jason Efstathiou, M.D., lead author of the study and a resident at the Harvard Radiation Oncology Program in Boston.
A PSA test is a blood test that measures the level of prostate specific antigen, a protein produced by the prostate. Increased levels of PSA may be a sign of prostate cancer.
The study took place between 1988 and 2002 and involved 1,492 men who were treated for prostate cancer by the surgical removal of their prostate and whose cancer came back. Among this group, 841 men had yearly PSA tests before their cancer diagnosis, while 611 men were diagnosed by other methods. There are large, randomized trials currently going in both the U.S. and Europe that will further confirm the impact of PSA screening tests among prostate cancer patients by 2008.
American Society for Therapeutic Radiology and Onc
A PSA test is a blood test that measures the level of prostate specific antigen, a protein produced by the prostate. Increased levels of PSA may be a sign of prostate cancer.
The study took place between 1988 and 2002 and involved 1,492 men who were treated for prostate cancer by the surgical removal of their prostate and whose cancer came back. Among this group, 841 men had yearly PSA tests before their cancer diagnosis, while 611 men were diagnosed by other methods. There are large, randomized trials currently going in both the U.S. and Europe that will further confirm the impact of PSA screening tests among prostate cancer patients by 2008.
American Society for Therapeutic Radiology and Onc
Prostate Cancer Screening Current Events and Prostate Cancer Screening News RSSNew finding suggests prostate biopsy is not always necessary
Researchers at Wake Forest University School of Medicine and the University of Wisconsin-Madison have discovered that some elevated prostate-specific antigen (PSA) levels in men may be caused by a hormone normally occurring in the body, and are not necessarily a predictor of the need for a prostate biopsy.
Experts issue call to reconsider screening for breast cancer and prostate cancer
Twenty years of screening for breast and prostate cancer - the most diagnosed cancer for women and men - have not brought the anticipated decline in deaths from these diseases, argue experts from the University of California, San Francisco and the University of Texas Health Science Center at San Antonio in an opinion piece published in the "Journal of the American Medical Association."
Physician trust, early screening reduces disparities for prostate cancer
Men who have a regular, ongoing relationship with a health care provider are more likely to receive prostate cancer screening and less likely to be diagnosed with advanced prostate cancer, regardless of their race, according to a University of North Carolina study published in the current issue of the journal Cancer.
Report: Prostate cancer screening has yet to prove its worth
The recent release of two large randomized trials suggests that if there is a benefit of screening, it is, at best, small.
Genetic marker may predict early onset of prostate cancer
Fox Chase Cancer Center researchers have identified a genetic marker that is associated with an earlier onset of prostate cancer in Caucasian men who have a family history of prostate cancer.
AUA counters mainstream recommendations with new best practice statement on PSA testing
he American Urological Association (AUA) today issued new clinical guidance - which directly contrasts recent recommendations issued by other major groups - about prostate cancer screening, asserting that the prostate-specific antigen (PSA) test should be offered to well-informed, men aged 40 years or older who have a life expectancy of at least 10 years.
U.S. trial shows no early mortality benefit from annual prostate cancer screening
The prostate cancer screening tests that have become an annual ritual for many men don't appear to reduce deaths from the disease among those with a limited life-expectancy, according to early results of a major U.S. study involving 75,000 men.
Racial disparities decline for cancer in Missouri
Cancer death rates in the United States are highest among African Americans, but a new report shows that in Missouri the disparity in cancer incidence and death between African Americans and whites is declining.
Anti-inflammatory drugs may mask prostate cancer marker
Regular use of nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin and ibuprofen, may reduce serum levels of the prostate biomarker, PSA (prostate specific antigen), and hence may alter the detection of prostate cancer in individuals who take these medications.
Health risk behaviors associated with lower prostate specific antigen awareness
According to a study conducted at Columbia University Mailman School of Public Health, health risk behaviors such as smoking and obesity are associated with lower awareness of the Prostate Specific Antigen (PSA), which could lead to a lower likelihood of undergoing actual prostate cancer screening.
More Prostate Cancer Screening Current Events and Prostate Cancer Screening News Articles
 |
Prostate Cancer Screening: Second Edition (Current Clinical Urology) by Donna Pauler Ankerst (Editor), Catherine M. Tangen (Editor), Ian M. Thompson Jr. (Editor) More than one in six men will develop prostate cancer in their lifetime. In recent years there has been an explosion of information regarding PSA screening and biomarkers for the disease. In Prostate Cancer Screening, Second Edition, the world’s leading experts on prostate cancer detection update the first edition with the latest findings. The book incorporates a series of thoughtful and cutting-edge works from the world’s experts in prostate cancer screening, ranging from the current status quo of prostate cancer screening across the globe to consensus on optimal utilization of the traditional PSA and DRE tests, to cutting-edge research in new biomarkers, biomeasures, and extended risk algorithms for prostate cancer. An additional chapter covers family-based linkage analysis as... |
|
Finding a better prostate cancer screening test: as questions swirl about the PSA test, doctors are turning to more finely tuned methods to accurately ... An article from: Focus on Healthy Aging by Gale Reference Team (Author) This digital document is an article from Focus on Healthy Aging, published by Thomson Gale on April 1, 2007. The length of the article is 628 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Finding a better prostate cancer screening test: as questions swirl about the PSA test, doctors are turning to more finely tuned methods to accurately predict aggressive cancers.(CANCER DETECTION) Author: Gale Reference Team Publication: Focus on Healthy Aging (Magazine/Journal) Date: April 1, 2007 Publisher: Thomson Gale Volume: 10 Issue: 4 Page: 7(1) Distributed by... | |
|
Prostate cancer screening, treatment revisited.(Men's Health): An article from: Family Practice News by Jeff Evans (Author) This digital document is an article from Family Practice News, published by International Medical News Group on June 1, 2005. The length of the article is 1349 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Prostate cancer screening, treatment revisited.(Men's Health) Author: Jeff Evans Publication: Family Practice News (Magazine/Journal) Date: June 1, 2005 Publisher: International Medical News Group Volume: 35 Issue: 11 Page: 56(1) Distributed by Thomson... | |
|
Prostate cancer screening.(Clinical Guidelines for Family Physicians): An article from: Family Practice News by Philip S. Perilstein (Author), Neil S. Skolnik (Author) This digital document is an article from Family Practice News, published by International Medical News Group on January 15, 2004. The length of the article is 793 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Prostate cancer screening.(Clinical Guidelines for Family Physicians) Author: Philip S. Perilstein Publication: Family Practice News (Magazine/Journal) Date: January 15, 2004 Publisher: International Medical News Group Volume: 34 Issue: 2 Page: 21(1) Distributed by Thomson... | |
|
Interpreting the PSA - the key to adequate prostate cancer screening. (prostate-specific antigen): An article from: Medical Update by Edwin W. Brown (Author) This digital document is an article from Medical Update, published by Benjamin Franklin Literary & Medical Society, Inc. on December 1, 1996. The length of the article is 1093 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Interpreting the PSA - the key to adequate prostate cancer screening. (prostate-specific antigen) Author: Edwin W. Brown Publication: Medical Update (Newsletter) Date: December 1, 1996 Publisher: Benjamin Franklin Literary & Medical Society, Inc. Volume: v20 Issue: n6 Page: p1(2) Distributed by Thomson... | |
|
Prostate cancer-screening saves lives.: An article from: Medical Update by Benjamin Franklin Literary & Medical Society, Inc. (Publisher) This digital document is an article from Medical Update, published by Benjamin Franklin Literary & Medical Society, Inc. on July 1, 2003. The length of the article is 1098 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Prostate cancer-screening saves lives. Publication: Medical Update (Newsletter) Date: July 1, 2003 Publisher: Benjamin Franklin Literary & Medical Society, Inc. Volume: 29 Issue: 1 Page: 1(2) Distributed by Thomson... | |
|
Costs And Effectiveness Of Prostate Cancer Screening In Elderly Men by Diane Pub Co (Publisher) | |
|
Prostate cancer--screening saves lives.(Interview): An article from: Indiana Business Magazine by Cory SerVaas (Author) This digital document is an article from Indiana Business Magazine, published by Curtis Magazine Group, Inc. on September 1, 2003. The length of the article is 687 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Prostate cancer--screening saves lives.(Interview) Author: Cory SerVaas Publication: Indiana Business Magazine (Magazine/Journal) Date: September 1, 2003 Publisher: Curtis Magazine Group, Inc. Volume: 47 Issue: 9 Page: S2(1) Article Type: Interview Distributed by Thomson... | |
|
Early data support tailored prostate cancer screening: low-risk men may need less PSA testing.(News)(prostate-specific antigen): An article from: Internal Medicine News by Kerri Wachter (Author) This digital document is an article from Internal Medicine News, published by Thomson Gale on August 15, 2006. The length of the article is 1513 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Early data support tailored prostate cancer screening: low-risk men may need less PSA testing.(News)(prostate-specific antigen) Author: Kerri Wachter Publication: Internal Medicine News (Magazine/Journal) Date: August 15, 2006 Publisher: Thomson Gale Volume: 39 Issue: 16 Page: 1(2) Distributed by Thomson... | |
|
Complexed PSA could cut prostate biopsies.(Prostate cancer screening)(Disease/Disorder overview): An article from: Internal Medicine News by John R. Bell (Author) This digital document is an article from Internal Medicine News, published by Thomson Gale on June 1, 2006. The length of the article is 574 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Complexed PSA could cut prostate biopsies.(Prostate cancer screening)(Disease/Disorder overview) Author: John R. Bell Publication: Internal Medicine News (Magazine/Journal) Date: June 1, 2006 Publisher: Thomson Gale Volume: 39 Issue: 11 Page: 42(1) Article Type: Disease/Disorder overview Distributed by Thomson... |
| © 2009 BrightSurf.com |